Literature DB >> 17118978

Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.

Alexander V Philipovskiy1, Stephen T Smiley.   

Abstract

Vaccination with live attenuated Yersinia pestis confers protection against pneumonic plague but is not considered safe for general use. Subunit plague vaccines containing the Y. pestis F1 and LcrV proteins prime robust antibody responses but may not provide sufficient protection. To aid the development of a safe and effective plague vaccine, we are investigating roles for T cells during defense against Y. pestis infection. Here we demonstrate that vaccination of mice with live Y. pestis primes specific CD4 and CD8 T cells that, upon purification and direct transfer to naïve mice, synergistically protect against lethal intranasal Y. pestis challenge. While not preventing extrapulmonary dissemination, the coadministered T cells promote bacterial clearance and reduce bacteremia. These observations strongly suggest that development of pneumonic plague vaccines should strive to prime both CD4 and CD8 T cells. Finally, we demonstrate that vaccination with live Y. pestis primes CD4 and CD8 T cells that respond to Y. pestis strains lacking the capacity to express F1, LcrV, and all pCD1/pPCP-encoded proteins, suggesting that protective T cells likely recognize antigens distinct from those previously defined as targets for humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118978      PMCID: PMC1828512          DOI: 10.1128/IAI.01529-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

Review 1.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

2.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.

Authors:  M Galimand; A Guiyoule; G Gerbaud; B Rasoamanana; S Chanteau; E Carniel; P Courvalin
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

Review 3.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

4.  Plague bacillus: survival within host phagocytes.

Authors:  W A Janssen; M J Surgalla
Journal:  Science       Date:  1969-02-28       Impact factor: 47.728

5.  Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

Authors:  K F Meyer; G Smith; L Foster; M Brookman; M Sung
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Pneumonic plague in an untreated plague-vaccinated individual.

Authors:  R J Cohen; J L Stockard
Journal:  JAMA       Date:  1967-10-23       Impact factor: 56.272

7.  Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar.

Authors:  M Ratsitorahina; S Chanteau; L Rahalison; L Ratsifasoamanana; P Boisier
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

8.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.

Authors:  A Roggenkamp; A M Geiger; L Leitritz; A Kessler; J Heesemann
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

Review 9.  Intraspecific diversity of Yersinia pestis.

Authors:  Andrey P Anisimov; Luther E Lindler; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

View more
  43 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

Review 3.  Interaction between Yersinia pestis and the host immune system.

Authors:  Bei Li; Ruifu Yang
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

4.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

5.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

6.  Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Authors:  Devender Kumar; Girish Kirimanjeswara; Dennis W Metzger
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

7.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

8.  Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta.

Authors:  Guang Tian; Zhizhen Qi; Yefeng Qiu; Xiaohong Wu; Qingwen Zhang; Xiaoyan Yang; Youquan Xin; Jian He; Yujing Bi; Qiong Wang; Jiyuan Zhou; Yanxiao Fan; Yazhou Zhou; Yongqiang Jiang; Ruifu Yang; Xiaoyi Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells.

Authors:  Georgia Perona-Wright; Katja Mohrs; Frank M Szaba; Lawrence W Kummer; Rajat Madan; Christopher L Karp; Lawrence L Johnson; Stephen T Smiley; Markus Mohrs
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

10.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.